A Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1

A Phase 2b Open-Label Rollover Study For Subjects Discontinuing From UK-453,061 Studies For The Treatment Of HIV-1 Infected Subjects

The purpose of the protocol is to assess long-term safety and tolerability of subjects who discontinue for any reason from UK-453,061 qualifying studies.

To assess long term safety and tolerability of subjects who discontinue for any reason from UK-453,061 studies. The study will also assess efficacy of the subsequent regimens in these patients. The trial was terminated prematurely on January 29, 2013, due to the decision of the sponsor to discontinue development of lersivirine. The decision to terminate the trial was not based on any safety or efficacy concerns.

Inclusion Criteria:

• Previous participation in a qualifying study.
• Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.

Exclusion Criteria:

• Concurrent treatment in another clinical trial.
• Unwilling or unable to be followed for 12 months